Prostate cancer treatment may harm your heart – new study investigates
NCT ID NCT05320406
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how certain hormone therapies for prostate cancer affect the heart. It compares two drugs, leuprolide and relugolix, given alongside radiation. The goal is to understand why some men develop heart problems and find ways to predict and reduce that risk. About 94 men with non-spreading prostate cancer are taking part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOCHEMICALLY RECURRENT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory Proton Therapy Center
Atlanta, Georgia, 30308, United States
-
Emory Saint Joseph's Hospital
Atlanta, Georgia, 30342, United States
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Emory University/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single small incision preserve sexual function after prostate cancer surgery?
- Precision radiation may tame rising PSA after prostate surgery
- Hormone therapy plus precision radiation aims to crush prostate cancer early
- Double-Dose precision: new combo radiation aims to shrink prostate tumors faster
- New scan could spot hidden aggressive prostate cancer in men who think They're safe
- New imaging agent aims to unmask hidden prostate cancer recurrences